Boston Scientific (NYSE:BSX) Stock Rating Raised to Hold at Barclays

Key Points

• Barclays upgraded Boston Scientific to “Hold,” while Wall Street’s broader view remains “Moderate Buy,” with 22 Buy, six Hold, and two Sell ratings and a consensus price target of $66.31.
• BSX shares opened at $41.55, near their 12-month low of $41.50 and below both the 50-day and 200-day moving averages, signaling continued selling pressure.
• The company exceeded quarterly expectations with $0.86 in earnings per share versus an $0.83 consensus and $5.44 billion in revenue; insiders also purchased roughly $9.4 million of shares over the past three months.

Boston Scientific (NYSE:BSX - Get Free Report) was upgraded by equities researchers at Barclays to a "hold" rating in a research note issued to investors on Wednesday, Zacks reports.

Several other analysts also recently weighed in on the stock. Robert W. Baird set a $56.00 target price on shares of Boston Scientific in a report on Thursday, July 30th. UBS Group lowered their price target on Boston Scientific from $74.00 to $67.00 and set a "buy" rating for the company in a research report on Thursday, July 30th. Jefferies Financial Group dropped their price objective on Boston Scientific from $100.00 to $67.00 and set a "buy" rating for the company in a research note on Wednesday, June 24th. TD Cowen reiterated a "buy" rating on shares of Boston Scientific in a report on Thursday, September 17th. Finally, Wall Street Zen lowered Boston Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, August 2nd. Twenty-two analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $66.31.

Boston Scientific Stock Down 1.5%

Shares of BSX opened at $41.55 on Wednesday. The company's 50-day moving average price is $46.72 and its 200 day moving average price is $50.90. Boston Scientific has a 12-month low of $41.50 and a 12-month high of $105.65. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The firm has a market cap of $60.21 billion, a P/E ratio of 16.82, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. Boston Scientific's revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, sell-side analysts forecast that Boston Scientific will post 3.25 earnings per share for the current year.

Insider Activity

In related news, Director David C. Habiger purchased 2,100 shares of Boston Scientific stock in a transaction on Wednesday, August 5th. The shares were bought at an average price of $47.59 per share, with a total value of $99,939.00. Following the transaction, the director directly owned 17,160 shares of the company's stock, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael F. Mahoney acquired 186,240 shares of the stock in a transaction dated Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares of the company's stock, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders have purchased 194,522 shares of company stock worth $9,385,210. Corporate insiders own 0.34% of the company's stock.

Institutional Trading of Boston Scientific

Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at $5,534,781,000. State Street Corp increased its holdings in Boston Scientific by 1.4% in the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider's stock valued at $6,278,422,000 after buying an additional 920,495 shares during the last quarter. Primecap Management Co. CA purchased a new position in Boston Scientific in the second quarter valued at $2,156,233,000. Jupiter Topco LLC acquired a new stake in Boston Scientific in the second quarter valued at $803,357,000. Finally, Janus Henderson Group PLC lifted its holdings in Boston Scientific by 31.0% during the 1st quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider's stock worth $1,035,202,000 after buying an additional 3,907,981 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific appointed longtime cardiovascular executive Joseph M. Fitzgerald as executive vice president and chief operating officer. Management said the change and new operating structure are intended to improve efficiency and support continued growth. Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
• Neutral Sentiment: The company is reorganizing operations into three segments, a move that could sharpen accountability and improve execution but also introduces near-term transition risk. Fitzgerald’s appointment is part of the restructuring, which includes changes involving the cardiovascular business. Boston Scientific names COO amid cardiovascular restructuring
• Neutral Sentiment: Barclays initiated coverage with an “equal weight” rating, signaling a balanced view rather than a strong bullish catalyst. The rating may limit enthusiasm while investors await evidence that the restructuring can reaccelerate growth. Barclays initiates coverage of Boston Scientific with equal-weight
• Negative Sentiment: Boston Scientific set a new 52-week low, reflecting sustained selling pressure and investor concern over the company’s growth outlook. Boston Scientific Sets New 52-Week Low
• Negative Sentiment: Citigroup issued a pessimistic forecast for BSX, adding to concerns that expectations may need to be reset. Separate analysis highlighted a sharp share-price decline, slowing WATCHMAN growth and the potential financial impact of a cyberattack as investor worries. Citigroup Issues Pessimistic Forecast for Boston Scientific Stock Price

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company's portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.